Utility and safety of procalcitonin in an antimicrobial stewardship program (ASP) in patients with malignancies
- 478 Downloads
As data on procalcitonin utility in antibiotics discontinuation [under an antimicrobial stewardship program (ASP)] in patients with malignancies are lacking, we aimed to evaluate the utility of procalcitonin in an ASP in patients with malignancies. We conducted a retrospective review of the ASP database of all patients with malignancies in whom at least one procalcitonin level was taken and our ASP had recommended changes in carbapenem regimen, from January to December 2011. We compared clinical outcomes between two groups of patients: patients whose physicians accepted and those whose physicians rejected ASP interventions. There were 749 carbapenem cases reviewed. Ninety-nine were suggested to either de-escalate, discontinue antibiotics, or narrow the spectrum of empiric treatment, based on procalcitonin trends. While there was no statistical difference in the mortality within 30 days post-ASP intervention (accepted: 8/65 patients vs. rejected: 9/34 patients; p = 0.076), the median duration of carbapenem therapy was significantly shorter (5 vs. 7 days; p = 0.002). Procalcitonin use safely facilitates decisions on antibiotics discontinuation and de-escalation in patients with malignancies in the ASP.
KeywordsFebrile Neutropenia Procalcitonin Carbapenem Antimicrobial Stewardship Program Procalcitonin Level
This study received no financial support of any type.
Conflict of interest
Kwa AL-H has received fundings for research from Janssen-Cilag, Pfizer, and Merck Sharp & Dohme (I.A.) Corp. The rest of the authors do not have any potential conflict of interest to declare.
- 4.Hsu L-Y, Tan T-Y, Tam VH, Kwa A, Fisher DA, Koh T-H; Network for Antimicrobial Resistance Surveillance (Singapore) (2010) Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother 54(3):1173–1178PubMedCrossRefGoogle Scholar
- 6.McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, Kaye KS, Fink JC, Langenberg P, Roghmann M-C, Harris AD (2005) Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol 161(5):483–493PubMedCrossRefGoogle Scholar
- 7.Rhee J-Y, Kwon KT, Ki HK, Shin SY, Jung DS, Chung D-R, Ha B-C, Peck KR, Song J-H (2009) Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 31(2):146–150PubMedCrossRefGoogle Scholar